KOD - Kodiak Sciences Inc.
Algert Global LLC increased its stake in shares of Kodiak Sciences Inc. (NASDAQ: KOD) by 26.1% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 186,476 shares of the company's stock after purchasing an additional 38,546 shares during the quarter.
KOD's Zenkuda advances toward regulatory submission as its pipeline gains momentum. Key clinical data is expected later in 2026.
PALO ALTO, Calif., Aug. 13, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended June 30, 2026.
Kodiak launches a global phase III study of KSI-501 in DME, testing its dual IL-6 and VEGF approach for durable disease control.
Phase 3 ALTO trial designed to demonstrate superiority of KSI-501 versus aflibercept in patients with diabetic macular edema PALO ALTO, Calif., Aug. 10, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that the first patients have been enrolled in the global Phase 3 ALTO trial evaluating KSI-501 in patients with diabetic macular edema (DME).
First pivotal cohort enrolled 300 subjects, with topline clinical data from 24-week primary endpoint on track for December 2026 release Completion of enrollment in the second pivotal cohort evaluating 600 subjects across the PEAK and PINNACLE studies is expected in 4Q 2026, with topline clinical data release anticipated in 2Q 2027 PALO ALTO, Calif., Aug. 6, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD) today announced that it has completed enrollment of the first 300-patient cohort in its PEAK trial, supporting Pivotal Analysis 1 of the KSI-101 Phase 3 program in macular edema secondary to inflammation ("MESI").
Shares of Kodiak Sciences Inc. (NASDAQ: KOD - Get Free Report) shot up 6.6% on Friday. The company traded as high as $43.94 and last traded at $43.9590. Approximately 68,404 shares changed hands during trading, a decline of 92% from the average session volume of 900,653 shares. The stock had previously closed at $41.25. Wall
Kodiak Sciences (KOD) is transitioning from past clinical disappointments to a maturing retina platform with multiple near-term catalysts. Recent GLOW2 Phase 3 success for Zenkuda in diabetic retinopathy and upcoming pivotal data for Zenkuda, KSI-501, and KSI-101 underpin a bullish outlook. KOD's current $169.5M cash position supports near-term catalysts, but additional capital will be needed for commercialization and late-stage development.
This clinical-stage biotech focused on retinal therapies reported a notable insider sale amid a year of exceptional stock performance.
KOD surges on positive phase III Zenkuda data, accelerated regulatory plans, advancing late-stage programs and a strengthened balance sheet.
PALO ALTO, Calif., May 28, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that Victor Perlroth, M.D.
This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through late-stage trials.
KOD posts a wider Q1 loss as research & development spending rises, while positive phase III Zenkuda data accelerate the regulatory plans.
PALO ALTO, Calif., May 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended March 31, 2026.
Clinical results of KSI-101 in macular edema secondary to inflammation (MESI) from a tertiary care uveitis practice demonstrate outcomes consistent with results from the U.S. Phase 1b APEX study, supporting continued global development and expansion of the Phase 3 PEAK and PINNACLE program into Asia. Ongoing advancement of bispecific therapies in geographic atrophy and ocular inflammatory disease; preclinical data continue to support a multi-target approach to address limitations of current single-target therapies.
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock?
KOD posts wider Q4 loss. However, its pipeline advances, with strong phase III data for Zenkuda driving accelerated regulatory plans.
PALO ALTO, Calif., March 31, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2025.
Kodiak Sciences' stock (NASDAQ: KOD) experienced a substantial 62% surge last week, elevating the stock to $37 and increasing its market capitalization to $2.3 billion. This impressive momentum was fueled by robust Phase 3 GLOW2 results for Zenkuda (tarcocimab), an experimental treatment aimed at retinal vascular disorders.
Kodiak Sciences Inc. (NASDAQ: KOD - Get Free Report) shares hit a new 52-week high during trading on Thursday. The company traded as high as $36.84 and last traded at $36.0160, with a volume of 3075248 shares. The stock had previously closed at $22.75. More Kodiak Sciences News Here are the key news stories impacting